This page is part of the Potential Drug-Drug Interaction (PDDI) Clinical Decision Support (CDS) (FHIR IG) (v0.2.0: STU 1 Ballot 2) based on FHIR R4. . For a full list of available versions, see the Directory of published versions

(DRAFT) Potential Drug-Drug Interaction (PDDI) CDS IG : Ballot for Comment 2

Valueset_methylprednisolone_exclude

Raw xml


<ValueSet xmlns="http://hl7.org/fhir">
  <id value="valueset-methylprednisolone-exclude"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><ul><li>Include these codes as defined in <a href="http://www.nlm.nih.gov/research/umls/rxnorm"><code>http://www.nlm.nih.gov/research/umls/rxnorm</code></a> version <code>02-Jul-2018</code><table class="none"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td>1100391</td><td>methylprednisolone acetate 0.01 MG/MG Topical Gel [HybriSil]</td><td/></tr><tr><td>1100390</td><td>Methylprednisolone Topical Gel [HybriSil]</td><td/></tr><tr><td>1358506</td><td>methylprednisolone acetate 0.0025 MG/MG Topical Ointment</td><td/></tr><tr><td>1100387</td><td>methylprednisolone acetate 0.01 MG/MG Topical Gel</td><td/></tr><tr><td>1100386</td><td>Methylprednisolone Topical Gel</td><td/></tr><tr><td>372863</td><td>Methylprednisolone Topical Ointment</td><td/></tr><tr><td>1163491</td><td>Methylprednisolone Topical Product</td><td/></tr><tr><td>1172713</td><td>HybriSil Topical Product</td><td/></tr></table></li></ul></div>
  </text>
  <url
       value="http://hl7.org/fhir/uv/pddi/ValueSet/valueset-methylprednisolone-exclude"/>
  <version value="0.2.0"/>
  <name value="Valueset_methylprednisolone_exclude"/>
  <title value="Exclude Methylprednisolone Medications Value Set"/>
  <status value="draft"/>
  <date value="2018-07-02"/>
  <publisher value="PDDI CDS"/>
  <contact>
    <name value="Richard Boyce"/>
  </contact>
  <description
               value="ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations."/>
  <jurisdiction>
    <coding>
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
      <code value="001"/>
      <display value="World"/>
    </coding>
  </jurisdiction>
  <purpose value="To refine valueset for Warfarin + NSAID PDDI-CDS"/>
  <copyright value="Attribution CC BY"/>
  <compose>
    <include>
      <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
      <version value="02-Jul-2018"/>
      <concept>
        <code value="1100391"/>
        <display
                 value="methylprednisolone acetate 0.01 MG/MG Topical Gel [HybriSil]"/>
      </concept>
      <concept>
        <code value="1100390"/>
        <display value="Methylprednisolone Topical Gel [HybriSil]"/>
      </concept>
      <concept>
        <code value="1358506"/>
        <display
                 value="methylprednisolone acetate 0.0025 MG/MG Topical Ointment"/>
      </concept>
      <concept>
        <code value="1100387"/>
        <display value="methylprednisolone acetate 0.01 MG/MG Topical Gel"/>
      </concept>
      <concept>
        <code value="1100386"/>
        <display value="Methylprednisolone Topical Gel"/>
      </concept>
      <concept>
        <code value="372863"/>
        <display value="Methylprednisolone Topical Ointment"/>
      </concept>
      <concept>
        <code value="1163491"/>
        <display value="Methylprednisolone Topical Product"/>
      </concept>
      <concept>
        <code value="1172713"/>
        <display value="HybriSil Topical Product"/>
      </concept>
    </include>
  </compose>
</ValueSet>